The goal of Cambridge-based Pockit Diagnostics is to improve medical diagnosis and treatment through the discovery of a new biomarkers for the detection of strokes. After conducting clinical trials, they have discovered two biomarkers with 95% accuracy to detect strokes with a simple drop of blood, and they plan to have it available to the NHS by 2024.
The first hour following a stroke is crucial for diagnosing the condition, but the next four hours are as crucial for administering the right care for each individual type of stroke in order to prevent long-term harm.
Pockit rapid test is essential because it will enable paramedics working in ambulances to quickly determine the type of stroke a patient has had. The outcomes inform the medical personnel where and how to proceed based on this early discovery. Early, thorough diagnosis ensures that the proper course of action will be prescribed and implemented as soon as possible.
Just a few hospitals in the UK are able to offer specific types of stroke patients the care they need; currently, transfer of patients to the right centre take too much time when that time is critical in providing the correct treatment. Pockit rapid test provides the best chance of receiving the appropriate medical care, with findings appearing in only a few minutes.
Since LVOs (Large Vessel Occlusion), account for 27% of all stroke events and are responsible for 95% of all stroke impairments, it is crucial to recognise and address them as soon as possible. According to the report released by the Stroke Association last month “More than 47,000 LVO patients will miss out on treatment on the NHS over the next seven years unless NHS England and ministers take immediate action”.
The Helen Hick Stroke Foundation is supporting this innovative study and research in the knowledge that it will benefit many potential stroke sufferers.